Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated at Leerink Partners

Leerink Partners began coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report published on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $15.00 price target on the stock.

A number of other brokerages have also recently weighed in on VYGR. Wedbush reduced their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, October 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, August 20th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $17.43.

Voyager Therapeutics Trading Up 0.7 %

NASDAQ VYGR opened at $8.07 on Wednesday. Voyager Therapeutics has a 12 month low of $5.71 and a 12 month high of $11.72. The stock has a 50-day simple moving average of $6.53 and a 200 day simple moving average of $7.70. The company has a market capitalization of $438.96 million, a PE ratio of -161.40 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The company had revenue of $29.58 million during the quarter, compared to analysts’ expectations of $11.52 million. During the same period in the prior year, the business posted ($0.51) EPS. As a group, sell-side analysts predict that Voyager Therapeutics will post -1.44 earnings per share for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at $500,525.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 4.53% of the stock is owned by insiders.

Institutional Trading of Voyager Therapeutics

Large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. raised its holdings in Voyager Therapeutics by 49.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after acquiring an additional 1,300 shares during the period. Plato Investment Management Ltd acquired a new stake in shares of Voyager Therapeutics during the 1st quarter worth $38,000. SG Americas Securities LLC bought a new position in Voyager Therapeutics in the 2nd quarter valued at about $85,000. ProShare Advisors LLC acquired a new position in shares of Voyager Therapeutics during the 1st quarter worth $101,000. Finally, Victory Capital Management Inc. boosted its stake in shares of Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after purchasing an additional 1,630 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.